Industry
Climb Bio, Inc.
Total Trials
6
Recruiting
4
Active
5
Completed
0
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
Failure Rate
0.0%
0 terminated/withdrawn out of 6 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed trials have results
Key Signals
4 recruiting
Enrollment Performance
Analytics
Phase 1
4(66.7%)
Early Phase 1
1(16.7%)
Phase 2
1(16.7%)
6Total
Phase 1(4)
Early Phase 1(1)
Phase 2(1)
Activity Timeline
Global Presence
Loading network data...
Clinical Trials (6)
Showing 6 of 6 trials
NCT07564596Phase 1Not Yet Recruiting
A Phase 1b/2a Study of Budoprutug in Systemic Lupus Erythematosus (SLE)
Role: lead
NCT07096843Phase 2Recruiting
A Phase 2 Study of Budoprutug in Subjects With Primary Membranous Nephropathy
Role: lead
NCT07043946Phase 1Recruiting
A Phase 1b/2a Study of Budoprutug in Subjects With Immune Thrombocytopenia (ITP)
Role: lead
NCT07011043Phase 1Recruiting
A Phase 1b Study of Budoprutug in Systemic Lupus Erythematosus (SLE)
Role: lead
NCT07090655Early Phase 1Active Not Recruiting
A Phase 1 Study of Budoprutug (TNT119) Subcutaneous and Intravenous Injections in Normal Healthy Volunteers
Role: lead
NCT07248865Phase 1Recruiting
A Phase 1 Study of CLYM116 in Normal Healthy Volunteers
Role: lead
All 6 trials loaded